Profil
Juan Camacho has founded two companies, Oncostellae SL in 2013 and Palobiofarma SL in 2003, where he holds the title of Director & Chief Scientific Officer.
Postes actifs de Juan Camacho
| Sociétés | Poste | Début |
|---|---|---|
Palobiofarma SL
 Palobiofarma SL Pharmaceuticals: MajorHealth Technology Palo Biofarma SL discovers and develops pharmaceutical products. Its pipeline consists of receptors which target pulmonary diseases, attention-deficit disorders, glaucoma, and degenerative conditions. The company was founded by Juan Camacho Gamez in 2006 and is headquartered in Noáin, Spain. | Fondateur | 26/08/2003 |
Anciens postes connus de Juan Camacho
| Sociétés | Poste | Fin |
|---|---|---|
Oncostellae SL
 Oncostellae SL Medical/Nursing ServicesHealth Services Oncostellae SL researches and develops drugs to treat cancer. It discovers and develops small molecule drugs for the treatment of cancer by generating pharmaceutical research programs around novel modulators of validated cancer targets like nuclear receptors. The company was founded by Mabel Loza, José Manuel Santamaría Pérez, Juan Camacho, Julio Castro-Palomina Laria, Jose Brea and Maribel Cadavid in 2013 and is headquartered in Ourense, Spain. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Palobiofarma SL
Palobiofarma SL Pharmaceuticals: MajorHealth Technology Palo Biofarma SL discovers and develops pharmaceutical products. Its pipeline consists of receptors which target pulmonary diseases, attention-deficit disorders, glaucoma, and degenerative conditions. The company was founded by Juan Camacho Gamez in 2006 and is headquartered in Noáin, Spain. | Health Technology |
Oncostellae SL
Oncostellae SL Medical/Nursing ServicesHealth Services Oncostellae SL researches and develops drugs to treat cancer. It discovers and develops small molecule drugs for the treatment of cancer by generating pharmaceutical research programs around novel modulators of validated cancer targets like nuclear receptors. The company was founded by Mabel Loza, José Manuel Santamaría Pérez, Juan Camacho, Julio Castro-Palomina Laria, Jose Brea and Maribel Cadavid in 2013 and is headquartered in Ourense, Spain. | Health Services |
